|Last Update: 05/22/13 - 3:16 PM EDT|
|YTD Performance: 13.57%|
|Previous Close: $61.31|
|52 Week Range: $49.79 - $66.06|
|Oustanding Shares: 817,529,000|
|Market Cap: 50,139,053,570|
|Qtr (06/13)||Qtr (09/13)||FY (12/13)||FY (12/14)|
|Number of Analysts||11||10||12||13|
|Growth Rate (Year over Year)||25.31%||6.57%||14.91%||14.97%|
A normally reliable short-term indicator looks bearish.
ESRX was upgraded from Hold to Buy, Jefferies said. $74 price target. Uncertainty is gone and the company should resume share repurchases.
ESRX estimates were raised through 2014, BMO Capital said. Company continues to execute on its plan. Market Perform rating and new $62 price target.
Express Scripts and McKesson could both see weakness.
For Walgreen, 2012's bad news was good news, while CVS remains an attractive investment choice.
ESRX estimates were boosted through 2014, Citigroup said. Company is keeping a tight lid on costs. Buy rating and new $64 price target.
These two solid names are finding support at their longer-term moving averages.
Shares of ESRX now seen reaching $65, according to Lazard Capital Markets. Estimates also upped, given better operating trends. Buy rating.
It’s much tougher to actually “buy low to sell high” than it is to espouse the concept.
ESRX still has a a historically low valuation.